Výsledky vyhledávání - "Anne Van Vreckem"

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors

Autor: R. Hoekstra, T.R. Jeffrey Evans, Jaap Verweij, Anne Van Vreckem, Maurizio Voi, Helen J. Mackay, Ferry A.L.M. Eskens, Donna Crawford, Walker J. Loos

Publikováno v: Clinical Cancer Research, 10, 2636-2644. American Association for Cancer Research Inc.

Purpose: BMS-214662 is a potent and selective inhibitor of the farnesyl transferase enzyme with in vitro and in vivo antitumor activity. The aims of this study were to characterize the toxicities and to determine the pharmacokinetic profiles of BMS-2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7e540304c026b18f3ea99425603fdaa
https://doi.org/10.1158/1078-0432.ccr-03-0327

Zobrazit plný text záznamu

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(11)

Purpose BMS-214662 is a potent, nonpeptide, small molecule inhibitor of human farnesyltransferase (FT). We have conducted a phase I pharmacokinetic (PK) and pharmacodynamic study of BMS-214662 administered intravenously weekly with 1- and 24-hour inf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b9f4661075329b8115891468ee545eb
https://pubmed.ncbi.nlm.nih.gov/15710949

Zobrazit plný text záznamu

Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer

Autor: Christian Peschel, Jeffrey S. Humphrey, Maurizio Tonato, Jean-Yves Douillard, Luis Paz-Ares, Maurizio Voi, Lesley Seymour, Anne Van Vreckem, Andrew Arnold, Katherine Young, Frances A. Shepherd, Dongsheng Tu, Michael Smylie, J. Ottaway, Mary Davis

Publikováno v: Lung cancer (Amsterdam, Netherlands). 46(3)

Background: This randomized, double-blind, placebo-controlled study was designed to assess whether the addition of the matrix metalloproteinase (MMP) inhibitor BMS-275291 to combined paclitaxel and carboplatin chemotherapy had an adverse impact on ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0746af3355f639398ecd0cecf68389bd
https://pubmed.ncbi.nlm.nih.gov/15541822

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání